Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Treasury Shares (2024 - 2025)

Prelude Therapeutics' Treasury Shares history spans 2 years, with the latest figure at $220500.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 292.0% year-over-year to $220500.0; the TTM value through Dec 2025 reached $220500.0, up 292.0%, while the annual FY2025 figure was $220500.0, 292.0% up from the prior year.
  • Treasury Shares for Q4 2025 was $220500.0 at Prelude Therapeutics, down from $292375.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $384875.0 in Q1 2025 and bottomed at $56250.0 in Q4 2024.